Contrafect Corporation (CFRX) 5.37 $CFRX
Contrafect net loss improves in Q4
Seeking Alpha - at Seeking Alpha - Mon Apr 06, 6:59AM CDT
CFRX: 5.37 (+0.09)
Contrafect Corp misses by $0.04
Seeking Alpha - at Seeking Alpha - Mon Apr 06, 6:39AM CDT
CFRX: 5.37 (+0.09)
ContraFect Corporation Announces Fourth Quarter and Full Year 2014 Results
Marketwired - Mon Apr 06, 6:30AM CDT
ContraFect Corporation (NASDAQ: CFRX) (NASDAQ: CFRXW) (NASDAQ: CFRXZ), a biotechnology company focused on the discovery and development of protein therapeutics and antibody products for life-threatening, drug-resistant infectious diseases, today announced results for the fourth quarter and full year ended December 31, 2014. The Company closed its initial public offering (IPO) on August 1, 2014 and ended 2014 with cash, cash equivalents and marketable securities of $27.4 million versus $4.1 million at the close of 2013.
CFRX: 5.37 (+0.09), CFRXW: 1.72 (-0.23)
How Alan Leong Of BioWatch News Keeps Successful Biotech Investing Simple
Life Sciences Report - Seeking Alpha - Thu Mar 05, 4:53PM CST
Biotechnology can be daunting to comprehend, but understanding is critical to successful investment. BioWatch News Founder Alan Leong has a nose for growth names, and his goal is to make their technology platforms clear to investors who might not...
CTRV: 3.12 (unch), GLMD: 9.14 (-0.72), PTBI: 3.78 (+0.15), CNAT: 6.66 (-0.15), GALT: 3.29 (-0.04), SRNE: 10.52 (-0.15), CELG: 118.71 (+2.62), GILD: 103.69 (-1.52), KITE: 60.58 (-0.35), CFRX: 5.37 (+0.09), ICPT: 283.20 (-2.22), JUNO: 56.66 (-1.06), CORT: 6.32 (-0.12)
ContraFect to Present at 27th Annual ROTH Conference
Marketwired - Tue Mar 03, 6:30AM CST
ContraFect Corporation (NASDAQ: CFRX) (NASDAQ: CFRXW) (NASDAQ: CFRXZ), a biotechnology company focused on the discovery and development of protein therapeutics and antibody products for life-threatening, drug-resistant infectious diseases, announced today that Julia P. Gregory, the Company's chief executive officer, will present a corporate overview at the 27th Annual ROTH Conference on Monday, March 9, 2015 at 9:30 AM PT (12:30 PM ET) in Dana Point, CA. Ms. Gregory will discuss its clinical program, CF-301, the Company's novel approach to the treatment of drug-resistant Staphylococcus aureus infections, including MRSA, and CF-404, a treatment for life-threatening influenza infections, covering all strains of influenza.
CFRX: 5.37 (+0.09), CFRXW: 1.72 (-0.23)
ContraFect to Present at 17th Annual BIO CEO & Investor Conference
Marketwired - Tue Feb 03, 6:31AM CST
ContraFect Corporation (NASDAQ: CFRX) (NASDAQ: CFRXW) (NASDAQ: CFRXZ), a biotechnology company focused on the discovery and development of protein therapeutics and antibody products for life-threatening, drug-resistant infectious diseases, announced today that Julia P. Gregory, the Company's chief executive officer, will present a corporate overview at the 17th Annual BIO CEO & Investor Conference on Monday, February 9, 2015 at 9:00 AM ET. Ms. Gregory will discuss ContraFect's lead programs, CF-301, the Company's novel treatment of drug-resistant Staphylococcus aureus infections, including MRSA, for which the U.S. Food and Drug Administration (FDA) recently approved the commencement of a Phase 1 clinical trial, and CF-404, a treatment for life-threatening influenza infections, covering all strains of influenza.
CFRX: 5.37 (+0.09), CFRXW: 1.72 (-0.23)
ContraFect: An Emerging Anti-Infectious Biotechnology Company With 2 Unique Platforms Targeting Multi-Drug Resistance
Tony Schwartz, PhD - at Seeking Alpha - Thu Jan 29, 10:06AM CST
CFRX: 5.37 (+0.09)
ContraFect to Present Company Overview, Including Clinical Plan for CF-301, at the 7th Annual Biotech Showcase
Marketwired - Wed Jan 07, 6:30AM CST
ContraFect Corporation (NASDAQ: CFRX) (NASDAQ: CFRXW) (NASDAQ: CFRXZ), a biotechnology company focused on the discovery and development of protein therapeutics and antibody products for life-threatening, drug-resistant infectious diseases, announced today that Julia P. Gregory, the Company's chief executive officer, will present a corporate overview at the 7th Annual Biotech Showcase in San Francisco, CA on Tuesday, January 13, 2015 at 10:30 AM PST (1:30 PM EST). Ms. Gregory will discuss ContraFect's lead programs, CF-301, the first novel approach to the treatment of drug-resistant Staphylococcus aureus infections, including MRSA, for which the U.S. Food and Drug Administration (FDA) approved the commencement of a Phase 1 clinical trial, and CF-404, a treatment for life-threatening influenza infections, covering all strains of influenza. Following the Company presentation, Ms. Gregory will participate on the plenary lunch session panel at 12:00 PM PST (3:00 PM EST). The topic of discussion for the plenary session is "How robust is the biotech rally and what could derail it?"
CFRX: 5.37 (+0.09), CFRXW: 1.72 (-0.23)
Midday Gainers / Losers
Seeking Alpha - at Seeking Alpha - Mon Dec 22, 11:50AM CST
ADXS: 23.34 (-0.27), SANW: 4.51 (+0.01), ASPS: 23.24 (+0.76), OCN: 7.74 (-0.15), ZAZA: 1.43 (+0.01), SGOC: 0.53 (-0.03), AAMC: 217.99 (-3.29), VOC: 6.20 (-0.18), TECU: 3.35 (+0.04), RDUS: 41.01 (-0.95), IRMD: 15.74 (-0.06), SKYS: 10.35 (-0.15), VSCI: 0.35 (-0.02), CALA: 13.41 (-0.35), REXX: 4.74 (-0.06), CFRX: 5.37 (+0.09), TRXC: 3.54 (-0.10), CHNR: 2.23 (unch), CNET: 1.64 (+0.04), DRYS: 0.73 (+0.02)
ContraFect Receives FDA Approval to Initiate Clinical Trials of CF-301 for MRSA Bloodstream Infections
Marketwired - Mon Dec 22, 6:30AM CST
ContraFect Corporation (NASDAQ: CFRX) (NASDAQ: CFRXW) (NASDAQ: CFRXZ), a biotechnology company focused on the discovery and development of protein therapeutics and antibody products for life-threatening, drug-resistant infectious diseases, announced today that the U.S. Food and Drug Administration (FDA) completed the review of its submission and has removed the full clinical hold on ContraFect's investigational new drug (IND) application for CF-301. This action allows for the initiation of clinical trials, which ContraFect expects to commence in Q1 2015.
CFRX: 5.37 (+0.09), CFRXW: 1.72 (-0.23)
ContraFect Corporation to Present at the Oppenheimer 25th Annual Healthcare Conference
Marketwired - Thu Dec 04, 6:30AM CST
ContraFect Corporation (NASDAQ: CFRX) (NASDAQ: CFRXW) (NASDAQ: CFRXZ), a biotechnology company focused on the discovery and development of protein therapeutics and antibody products for life-threatening, drug-resistant infectious diseases, announced today that Julia P. Gregory, the Company's chief executive officer, will present a corporate overview at the Oppenheimer 25th Annual Healthcare Conference in New York, NY on Wednesday, December 10, 2014 at 4:30 PM ET. Ms. Gregory will discuss ContraFect's lead programs, CF-301, which provides a novel approach to the treatment of drug-resistant Staphylococcus aureus infections and CF-404, a universal treatment for life-threatening influenza infections.
CFRX: 5.37 (+0.09), CFRXW: 1.72 (-0.23)
ContraFect Submits Complete Response to IND Clinical Hold for CF-301
Marketwired - Tue Dec 02, 6:30AM CST
ContraFect Corporation (NASDAQ: CFRX) (NASDAQ: CFRXW) (NASDAQ: CFRXZ), a biotechnology company focused on the discovery and development of protein therapeutics and antibody products for life-threatening, drug-resistant infectious diseases, announced today that it has submitted a complete response to the U.S. Food and Drug Administration (FDA). The complete response addresses all of the issues identified in the Investigational New Drug Application (IND) clinical hold letter issued by FDA.
CFRX: 5.37 (+0.09), CFRXW: 1.72 (-0.23)
Contrafect reports Q3 earnings
Seeking Alpha - at Seeking Alpha - Fri Nov 14, 4:43PM CST
CFRX: 5.37 (+0.09)
ContraFect Corporation Announces Third Quarter 2014 Results
Marketwired - Fri Nov 14, 4:40PM CST
ContraFect Corporation (NASDAQ: CFRX) (NASDAQ: CFRXW) (NASDAQ: CFRXZ), a biotechnology company focused on the discovery and development of protein therapeutics and antibody products for life-threatening, drug-resistant infectious diseases, today announced results for the third quarter ended September 30, 2014. The Company closed its initial public offering (IPO) on August 1, 2014. For the three month period ended September 30, 2014, the Company posted a net loss of $16.4 million. Cash and cash equivalents totaled $31.3 million at the end of the quarter.
CFRX: 5.37 (+0.09), CFRXW: 1.72 (-0.23)
ContraFect and National Institute for Viral Disease Control and Prevention, China CDC Sign Agreement to Collaborate on Universal Influenza Treatment
Marketwired - Thu Oct 09, 6:30AM CDT
ContraFect Corporation (NASDAQ: CFRX) (NASDAQ: CFRXW) (NASDAQ: CFRXZ), a biotechnology company focused on the discovery and development of protein therapeutics and antibody products for life-threatening, drug-resistant infectious diseases, announced today that they have entered into a collaborative research agreement with the National Institute for Viral Disease Control and Prevention, China CDC ("IVDC"
to advance research and development of CF-404, its Universal Influenza Treatment.
CFRX: 5.37 (+0.09), CFRXW: 1.72 (-0.23)
ContraFect Corporation to Present at the 13th Annual BIO Investor Forum
Marketwire - Tue Sep 30, 6:30AM CDT
ContraFect Corporation (NASDAQ: CFRX) (NASDAQ: CFRXW) (NASDAQ: CFRXZ), a biotechnology company focused on the discovery and development of protein therapeutics and antibody products for life-threatening, drug resistant infectious diseases, announced today that Julia P. Gregory, the Company's chief executive officer and Barry Kappel, the Company's senior vice president of business development, will present a corporate overview at the 13th Annual BIO Investor Forum at The Palace Hotel in San Francisco, CA on Tuesday, October 7 at 3:30 PM PT. Ms. Gregory and Dr. Kappel will discuss ContraFect's lead programs: CF-301, which provides a novel approach to the treatment of drug-resistant Staphylococcus aureus infections, including MRSA; and CF-404, a universal treatment for life-threatening influenza infections.
CFRX: 5.37 (+0.09), CFRXW: 1.72 (-0.23)
ContraFect Corporation Expands Senior Management Team
Marketwire - Wed Sep 24, 6:30AM CDT
ContraFect Corporation (NASDAQ: CFRX) (NASDAQ: CFRXW) (NASDAQ: CFRXZ), a biotechnology company focused on the discovery and development of protein therapeutics and antibody products for life-threatening drug resistant infectious diseases, announced today it has expanded the senior management of the company with the addition of Natalie Bogdanos. Ms. Bogdanos joined ContraFect as General Counsel.
CFRX: 5.37 (+0.09), CFRXW: 1.72 (-0.23)
ContraFect Corporation to Present at BioCentury's 21st Annual NewsMakers in the Biotech Industry Conference
Marketwire - Fri Sep 19, 6:30AM CDT
ContraFect Corporation (NASDAQ: CFRX) (NASDAQ: CFRXW) (NASDAQ: CFRXZ), a biotechnology company focused on protein and antibody therapeutic products for life-threatening infectious diseases, announced today that Julia P. Gregory, the Company's chief executive officer and Barry Kappel, the Company's senior vice president of business development, will present a corporate overview at BioCentury's 21st Annual NewsMakers in the Biotech Industry Conference at the Millennium Broadway Hotel in New York, NY on Friday, September 26 at 8:30 AM EST. Ms. Gregory and Dr. Kappel will discuss ContraFect's lead programs, CF-301, which provides a novel approach to the treatment of drug-resistant Staphylococcus aureus infections and CF-404, a universal treatment for life-threatening influenza infections.
CFRX: 5.37 (+0.09), CFRXW: 1.72 (-0.23)
ContraFect Corporation's Universal Influenza Treatment Receives SBIR Funding
Marketwire - Tue Sep 16, 6:30AM CDT
ContraFect Corporation (NASDAQ: CFRX) (NASDAQ: CFRXW) (NASDAQ: CFRXZ), a biotechnology company focused on the discovery and development of protein therapeutics and antibody products for life-threatening, drug-resistant infectious diseases, announced that CF-404, its universal influenza treatment, received a $3.3 million, 3.5 year Advanced Technology Fast Track Small Business Innovation Research (SBIR) grant from the National Institute of Allergy and Infectious Diseases (NIAID) to fund its pre-clinical development. Trellis Bioscience, LLC, with which ContraFect collaborated to create and then in-licensed the universal influenza treatment, obtained the grant (grant #1R44AI106077-01A1) and Larry Kauvar, PhD, Trellis VP and Chief Scientific Officer, is the Principal Investigator on these studies.
CFRX: 5.37 (+0.09), CFRXW: 1.72 (-0.23)
Contrafect net loss improves in Q4
Seeking Alpha - at Seeking Alpha - Mon Apr 06, 6:59AM CDT
CFRX: 5.37 (+0.09)
Contrafect Corp misses by $0.04
Seeking Alpha - at Seeking Alpha - Mon Apr 06, 6:39AM CDT
CFRX: 5.37 (+0.09)
ContraFect Corporation Announces Fourth Quarter and Full Year 2014 Results
Marketwired - Mon Apr 06, 6:30AM CDT
ContraFect Corporation (NASDAQ: CFRX) (NASDAQ: CFRXW) (NASDAQ: CFRXZ), a biotechnology company focused on the discovery and development of protein therapeutics and antibody products for life-threatening, drug-resistant infectious diseases, today announced results for the fourth quarter and full year ended December 31, 2014. The Company closed its initial public offering (IPO) on August 1, 2014 and ended 2014 with cash, cash equivalents and marketable securities of $27.4 million versus $4.1 million at the close of 2013.
CFRX: 5.37 (+0.09), CFRXW: 1.72 (-0.23)
How Alan Leong Of BioWatch News Keeps Successful Biotech Investing Simple
Life Sciences Report - Seeking Alpha - Thu Mar 05, 4:53PM CST
Biotechnology can be daunting to comprehend, but understanding is critical to successful investment. BioWatch News Founder Alan Leong has a nose for growth names, and his goal is to make their technology platforms clear to investors who might not...
CTRV: 3.12 (unch), GLMD: 9.14 (-0.72), PTBI: 3.78 (+0.15), CNAT: 6.66 (-0.15), GALT: 3.29 (-0.04), SRNE: 10.52 (-0.15), CELG: 118.71 (+2.62), GILD: 103.69 (-1.52), KITE: 60.58 (-0.35), CFRX: 5.37 (+0.09), ICPT: 283.20 (-2.22), JUNO: 56.66 (-1.06), CORT: 6.32 (-0.12)
ContraFect to Present at 27th Annual ROTH Conference
Marketwired - Tue Mar 03, 6:30AM CST
ContraFect Corporation (NASDAQ: CFRX) (NASDAQ: CFRXW) (NASDAQ: CFRXZ), a biotechnology company focused on the discovery and development of protein therapeutics and antibody products for life-threatening, drug-resistant infectious diseases, announced today that Julia P. Gregory, the Company's chief executive officer, will present a corporate overview at the 27th Annual ROTH Conference on Monday, March 9, 2015 at 9:30 AM PT (12:30 PM ET) in Dana Point, CA. Ms. Gregory will discuss its clinical program, CF-301, the Company's novel approach to the treatment of drug-resistant Staphylococcus aureus infections, including MRSA, and CF-404, a treatment for life-threatening influenza infections, covering all strains of influenza.
CFRX: 5.37 (+0.09), CFRXW: 1.72 (-0.23)
ContraFect to Present at 17th Annual BIO CEO & Investor Conference
Marketwired - Tue Feb 03, 6:31AM CST
ContraFect Corporation (NASDAQ: CFRX) (NASDAQ: CFRXW) (NASDAQ: CFRXZ), a biotechnology company focused on the discovery and development of protein therapeutics and antibody products for life-threatening, drug-resistant infectious diseases, announced today that Julia P. Gregory, the Company's chief executive officer, will present a corporate overview at the 17th Annual BIO CEO & Investor Conference on Monday, February 9, 2015 at 9:00 AM ET. Ms. Gregory will discuss ContraFect's lead programs, CF-301, the Company's novel treatment of drug-resistant Staphylococcus aureus infections, including MRSA, for which the U.S. Food and Drug Administration (FDA) recently approved the commencement of a Phase 1 clinical trial, and CF-404, a treatment for life-threatening influenza infections, covering all strains of influenza.
CFRX: 5.37 (+0.09), CFRXW: 1.72 (-0.23)
ContraFect: An Emerging Anti-Infectious Biotechnology Company With 2 Unique Platforms Targeting Multi-Drug Resistance
Tony Schwartz, PhD - at Seeking Alpha - Thu Jan 29, 10:06AM CST
CFRX: 5.37 (+0.09)
ContraFect to Present Company Overview, Including Clinical Plan for CF-301, at the 7th Annual Biotech Showcase
Marketwired - Wed Jan 07, 6:30AM CST
ContraFect Corporation (NASDAQ: CFRX) (NASDAQ: CFRXW) (NASDAQ: CFRXZ), a biotechnology company focused on the discovery and development of protein therapeutics and antibody products for life-threatening, drug-resistant infectious diseases, announced today that Julia P. Gregory, the Company's chief executive officer, will present a corporate overview at the 7th Annual Biotech Showcase in San Francisco, CA on Tuesday, January 13, 2015 at 10:30 AM PST (1:30 PM EST). Ms. Gregory will discuss ContraFect's lead programs, CF-301, the first novel approach to the treatment of drug-resistant Staphylococcus aureus infections, including MRSA, for which the U.S. Food and Drug Administration (FDA) approved the commencement of a Phase 1 clinical trial, and CF-404, a treatment for life-threatening influenza infections, covering all strains of influenza. Following the Company presentation, Ms. Gregory will participate on the plenary lunch session panel at 12:00 PM PST (3:00 PM EST). The topic of discussion for the plenary session is "How robust is the biotech rally and what could derail it?"
CFRX: 5.37 (+0.09), CFRXW: 1.72 (-0.23)
Midday Gainers / Losers
Seeking Alpha - at Seeking Alpha - Mon Dec 22, 11:50AM CST
ADXS: 23.34 (-0.27), SANW: 4.51 (+0.01), ASPS: 23.24 (+0.76), OCN: 7.74 (-0.15), ZAZA: 1.43 (+0.01), SGOC: 0.53 (-0.03), AAMC: 217.99 (-3.29), VOC: 6.20 (-0.18), TECU: 3.35 (+0.04), RDUS: 41.01 (-0.95), IRMD: 15.74 (-0.06), SKYS: 10.35 (-0.15), VSCI: 0.35 (-0.02), CALA: 13.41 (-0.35), REXX: 4.74 (-0.06), CFRX: 5.37 (+0.09), TRXC: 3.54 (-0.10), CHNR: 2.23 (unch), CNET: 1.64 (+0.04), DRYS: 0.73 (+0.02)
ContraFect Receives FDA Approval to Initiate Clinical Trials of CF-301 for MRSA Bloodstream Infections
Marketwired - Mon Dec 22, 6:30AM CST
ContraFect Corporation (NASDAQ: CFRX) (NASDAQ: CFRXW) (NASDAQ: CFRXZ), a biotechnology company focused on the discovery and development of protein therapeutics and antibody products for life-threatening, drug-resistant infectious diseases, announced today that the U.S. Food and Drug Administration (FDA) completed the review of its submission and has removed the full clinical hold on ContraFect's investigational new drug (IND) application for CF-301. This action allows for the initiation of clinical trials, which ContraFect expects to commence in Q1 2015.
CFRX: 5.37 (+0.09), CFRXW: 1.72 (-0.23)
ContraFect Corporation to Present at the Oppenheimer 25th Annual Healthcare Conference
Marketwired - Thu Dec 04, 6:30AM CST
ContraFect Corporation (NASDAQ: CFRX) (NASDAQ: CFRXW) (NASDAQ: CFRXZ), a biotechnology company focused on the discovery and development of protein therapeutics and antibody products for life-threatening, drug-resistant infectious diseases, announced today that Julia P. Gregory, the Company's chief executive officer, will present a corporate overview at the Oppenheimer 25th Annual Healthcare Conference in New York, NY on Wednesday, December 10, 2014 at 4:30 PM ET. Ms. Gregory will discuss ContraFect's lead programs, CF-301, which provides a novel approach to the treatment of drug-resistant Staphylococcus aureus infections and CF-404, a universal treatment for life-threatening influenza infections.
CFRX: 5.37 (+0.09), CFRXW: 1.72 (-0.23)
ContraFect Submits Complete Response to IND Clinical Hold for CF-301
Marketwired - Tue Dec 02, 6:30AM CST
ContraFect Corporation (NASDAQ: CFRX) (NASDAQ: CFRXW) (NASDAQ: CFRXZ), a biotechnology company focused on the discovery and development of protein therapeutics and antibody products for life-threatening, drug-resistant infectious diseases, announced today that it has submitted a complete response to the U.S. Food and Drug Administration (FDA). The complete response addresses all of the issues identified in the Investigational New Drug Application (IND) clinical hold letter issued by FDA.
CFRX: 5.37 (+0.09), CFRXW: 1.72 (-0.23)
Contrafect reports Q3 earnings
Seeking Alpha - at Seeking Alpha - Fri Nov 14, 4:43PM CST
CFRX: 5.37 (+0.09)
ContraFect Corporation Announces Third Quarter 2014 Results
Marketwired - Fri Nov 14, 4:40PM CST
ContraFect Corporation (NASDAQ: CFRX) (NASDAQ: CFRXW) (NASDAQ: CFRXZ), a biotechnology company focused on the discovery and development of protein therapeutics and antibody products for life-threatening, drug-resistant infectious diseases, today announced results for the third quarter ended September 30, 2014. The Company closed its initial public offering (IPO) on August 1, 2014. For the three month period ended September 30, 2014, the Company posted a net loss of $16.4 million. Cash and cash equivalents totaled $31.3 million at the end of the quarter.
CFRX: 5.37 (+0.09), CFRXW: 1.72 (-0.23)
ContraFect and National Institute for Viral Disease Control and Prevention, China CDC Sign Agreement to Collaborate on Universal Influenza Treatment
Marketwired - Thu Oct 09, 6:30AM CDT
ContraFect Corporation (NASDAQ: CFRX) (NASDAQ: CFRXW) (NASDAQ: CFRXZ), a biotechnology company focused on the discovery and development of protein therapeutics and antibody products for life-threatening, drug-resistant infectious diseases, announced today that they have entered into a collaborative research agreement with the National Institute for Viral Disease Control and Prevention, China CDC ("IVDC"
to advance research and development of CF-404, its Universal Influenza Treatment. CFRX: 5.37 (+0.09), CFRXW: 1.72 (-0.23)
ContraFect Corporation to Present at the 13th Annual BIO Investor Forum
Marketwire - Tue Sep 30, 6:30AM CDT
ContraFect Corporation (NASDAQ: CFRX) (NASDAQ: CFRXW) (NASDAQ: CFRXZ), a biotechnology company focused on the discovery and development of protein therapeutics and antibody products for life-threatening, drug resistant infectious diseases, announced today that Julia P. Gregory, the Company's chief executive officer and Barry Kappel, the Company's senior vice president of business development, will present a corporate overview at the 13th Annual BIO Investor Forum at The Palace Hotel in San Francisco, CA on Tuesday, October 7 at 3:30 PM PT. Ms. Gregory and Dr. Kappel will discuss ContraFect's lead programs: CF-301, which provides a novel approach to the treatment of drug-resistant Staphylococcus aureus infections, including MRSA; and CF-404, a universal treatment for life-threatening influenza infections.
CFRX: 5.37 (+0.09), CFRXW: 1.72 (-0.23)
ContraFect Corporation Expands Senior Management Team
Marketwire - Wed Sep 24, 6:30AM CDT
ContraFect Corporation (NASDAQ: CFRX) (NASDAQ: CFRXW) (NASDAQ: CFRXZ), a biotechnology company focused on the discovery and development of protein therapeutics and antibody products for life-threatening drug resistant infectious diseases, announced today it has expanded the senior management of the company with the addition of Natalie Bogdanos. Ms. Bogdanos joined ContraFect as General Counsel.
CFRX: 5.37 (+0.09), CFRXW: 1.72 (-0.23)
ContraFect Corporation to Present at BioCentury's 21st Annual NewsMakers in the Biotech Industry Conference
Marketwire - Fri Sep 19, 6:30AM CDT
ContraFect Corporation (NASDAQ: CFRX) (NASDAQ: CFRXW) (NASDAQ: CFRXZ), a biotechnology company focused on protein and antibody therapeutic products for life-threatening infectious diseases, announced today that Julia P. Gregory, the Company's chief executive officer and Barry Kappel, the Company's senior vice president of business development, will present a corporate overview at BioCentury's 21st Annual NewsMakers in the Biotech Industry Conference at the Millennium Broadway Hotel in New York, NY on Friday, September 26 at 8:30 AM EST. Ms. Gregory and Dr. Kappel will discuss ContraFect's lead programs, CF-301, which provides a novel approach to the treatment of drug-resistant Staphylococcus aureus infections and CF-404, a universal treatment for life-threatening influenza infections.
CFRX: 5.37 (+0.09), CFRXW: 1.72 (-0.23)
ContraFect Corporation's Universal Influenza Treatment Receives SBIR Funding
Marketwire - Tue Sep 16, 6:30AM CDT
ContraFect Corporation (NASDAQ: CFRX) (NASDAQ: CFRXW) (NASDAQ: CFRXZ), a biotechnology company focused on the discovery and development of protein therapeutics and antibody products for life-threatening, drug-resistant infectious diseases, announced that CF-404, its universal influenza treatment, received a $3.3 million, 3.5 year Advanced Technology Fast Track Small Business Innovation Research (SBIR) grant from the National Institute of Allergy and Infectious Diseases (NIAID) to fund its pre-clinical development. Trellis Bioscience, LLC, with which ContraFect collaborated to create and then in-licensed the universal influenza treatment, obtained the grant (grant #1R44AI106077-01A1) and Larry Kauvar, PhD, Trellis VP and Chief Scientific Officer, is the Principal Investigator on these studies.
CFRX: 5.37 (+0.09), CFRXW: 1.72 (-0.23)
